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Abstract
Hemoglobin glycation index (HGI), defined as the difference between the observed HbA1c
value and the value of HbA1c predicted from plasma glucose levels, represents a measure
of the degree of non-enzymatic glycation of hemoglobin and it has been found to be posi-
tively associated with micro- and macro-vascular complications in subjects with type 2 dia-
betes. To investigate the pathophysiological abnormalities responsible for the increased
cardiovascular risk of patients with higher HGI, we evaluated the association of HGI with
cardio-metabolic characteristics in nondiabetic offspring of type 2 diabetic individuals. Insu-
lin sensitivity, measured by a hyperinsulinemic-euglycemic clamp, cardio-metabolic risk fac-
tors including lipid profile, uric acid and inflammatory factors, and ultrasound measurement
of carotid intima–media thickness (IMT) were assessed in 387 nondiabetic individuals. Par-
ticipants were stratified in tertiles according to HGI (high, moderate and low). As compared
with subjects with low HGI, those with high HGI displayed an unfavorable cardio-metabolic
risk profile having significantly higher values of BMI, waist circumference, triglycerides, uric
acid, fasting insulin, inflammatory markers, such as high sensitivity C reactive protein, eryth-
rocytes sedimentation rate, complement C3, fibrinogen, and white blood cell count, and
carotid IMT, and lower HDL and insulin-stimulated glucose disposal. In a linear regression
analysis model including several atherosclerotic risk factors such as gender, age, BMI,
inflammatory factors, lipid profile, insulin-stimulated glucose disposal, fasting insulin, uric
acid, and blood pressure, HGI was the major predictor of IMT (β = 0.35; P = 0.001). In a
logistic regression analysis adjusted for confounders, individuals with high HGI showed a
2.7-fold increased risk of vascular atherosclerosis (OR 2.72, 95%CI 1.01–7.37) as com-
pared with subjects with low HGI. The present findings support the notion that HGI may be a
useful tool to identify a subset of nondiabetic individuals conceivably harboring a higher risk
of cardiovascular disease.
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Introduction
Glycated hemoglobin (HbA1c) test is an indirect measure of average glycemia over approxi-
mately the previous 3 months that has been recommended not only for monitoring glucose
control among persons with diabetes but also as a diagnostic test for both type 2 diabetes and
conditions of increased risk of diabetes (the so-called prediabetes) [1]. Compared with fasting
glucose or 2-h post load glucose values, HbA1c has some advantages as a diagnostic test since
it has higher repeatability and pre-analytical stability, it can be measured in the nonfasting
state, and has less day-to-day perturbations during illness conditions. In addition, HbA1c has
been shown to be a better predictor of cardiovascular disease than fasting plasma glucose even
in nondiabetic populations [2,3]. Nonetheless, discordances between HbA1c values and other
measures of glycemic control have been observed [4–7]. Indeed, inter-individual variations in
HbA1c caused by factors other than blood glucose concentration have been reported in sub-
jects with type 2 diabetes [8–10], and in nondiabetic individuals [11–18]; these variants were
likely due to genetic factors [15,16] or to differences in hemoglobin glycation rates or in red
cell survival among different ethnic groups [17,18].
A statistical method to measure the disparity between actual HbA1c and the predicted
value of HbA1c based on plasma glucose levels has been developed and termed hemoglobin
glycation index (HGI) [19–22]. HGI is calculated as the difference between the observed
HbA1c value and the predicted HbA1c derived by inserting the individual fasting plasma glu-
cose concentration into a population regression equation expressing the linear association
between HbA1c and plasma glucose levels [19,22]. HGI may help to identify diabetic subjects
with a greater risk of micro- and macro-vascular complications [21,22]. Applying HGI analysis
to the Diabetes Control and Complications Trial (DCCT), it has been observed that type 1 dia-
betic patients with a high HGI exhibited a greater risk for retinopathy and nephropathy [21].
Accordingly, in patients with type 2 diabetes participating to the Action to Control Cardiovas-
cular Risk in Diabetes (ACCORD) trial, a higher HGI value was found to be associated with
retinopathy and nephropathy at baseline, and with greater mortality in the intensive treatment
group [22].
The question arises whether disparities between HbA1c and fasting plasma glucose as
assessed by HGI may unveil a different cardio-metabolic risk profile within nondiabetic
individuals.
To gain a deeper insight into the pathophysiological abnormalities responsible for the
increased risk of cardiovascular complications observed in type 2 diabetic patients with higher
HGI [22], we evaluated the associations of HGI with cardio-metabolic characteristics including
insulin sensitivity, assessed by the hyperinsulinemic-euglycemic clamp technique, lipid profile,
inflammatory factors, and carotid intima-media thickness (IMT) in a cohort of non-diabetic
offspring of type 2 diabetic individuals.
Materials and methods
Study subjects
Two different samples of White nondiabetic adults (18 years of age) were studied.
Sample 1 comprises 2,055 nondiabetic individuals consecutively recruited at the Depart-
ment of Systems Medicine of the University of Rome-Tor Vergata and at the Department of
Medical and Surgical Sciences of the University “Magna Graecia” of Catanzaro [23]. This sam-
ple was used to estimate the linear relationship between fasting plasma glucose and HbA1c
in the study population to calculate the predicted HbA1c value [22]. The inclusion criteria
were: age20 years, absence of diabetes, defined as HbA1c6.5% or fasting plasma glucose
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126mg/dl, and presence of one or more cardio-metabolic risk factors including elevated
blood pressure, dyslipidemia, overweight/obesity, and family history for diabetes. Exclusion
criteria encompassed: history of any malignant disease, end stage renal disease, heart failure,
gastrointestinal diseases associated with bleeding or malabsorption, autoimmune diseases,
acute or chronic infections, acute or chronic pancreatitis, haemoglobinopathies including
beta thalassemia trait, erythrocyte disorders, accumulation diseases such as amyloidosis and
hemochromatosis, history of drug abuse, self-reporting alcohol consumption of>20 g/day,
positivity for antibodies to hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg),
treatments able to modulate glucose metabolism, including lipid-lowering and hypoglycemic
agents, corticosteroids, and use of antiplatelet or anticoagulant medications.
Sample 2 comprises 387 non-diabetic offspring subjects participating in the European Net-
work on Functional Genomics of Type 2 Diabetes (EUGENE2) project [24] who had only one
parent with type 2 diabetes. Subjects were consecutively recruited at the Department of Medi-
cal and Surgical Sciences of the University ‘Magna Graecia’ of Catanzaro and at the Depart-
ment of Systems Medicine, University of Tor Vergata, Rome as previously described [25].
Participants underwent anthropometrical evaluation including measurements of body mass
index (BMI), waist circumference, body composition evaluated by bioelectrical impedance,
and three consecutive measurements of clinic blood pressure were obtained in the sitting posi-
tion, after five minutes of quiet rest. Resting heart rate was measured in the morning with sub-
jects in the supine position, after at least 30 min of quiet rest, by electrocardiography. After
12-h fasting, a 75 g OGTT was performed with sampling for plasma glucose and insulin deter-
minations. Insulin sensitivity was assessed by euglycemic hyperinsulinemic clamp study, as
previously described [26]. Briefly, a priming dose of insulin (Humulin, Eli Lilly & Co., India-
napolis, IN) was administrated during the initial 10 min to acutely raise plasma insulin fol-
lowed by continuous insulin infusion fixed at 40 mU/m2 x min. The blood glucose level was
maintained constant during the 2-h clamp study by infusing 20% glucose at varying rates
according to blood glucose measurements obtained with a glucose analyzer at 5 minute inter-
vals (mean coefficient of variation of blood glucose was < 5%). Glucose disposal (M) was cal-
culated as the mean rate of glucose infusion measured during the last 60 min of the clamp
examination (steady-state) and it is expressed as milligrams per minute per kilogram fat-free
mass (MFFM) measured with the use of electrical bioimpedance. High resolution B-mode ultra-
sound was used to measure IMT of the common carotid artery using an ATL HDI 3000 ultra-
sound system (Advanced Technology Laboratories, Bothell, WA) equipped with a 7.5 MHz
transducer, as previously described [27]. A value of IMT >0.9 mm was used as index of vascu-
lar atherosclerosis according to the 2013 Guidelines for the management of arterial hyperten-
sion released by the Task Force for the Management of Arterial Hypertension of the European
Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [28].
The protocol was approved by Institutional Ethics Committees and written informed con-
sent was obtained from all participants in accordance with principles of the Declaration of
Helsinki.
Analytical determinations
HbA1c was measured with high performance liquid chromatography using a National Glyco-
hemoglobin Standardization Program (NGSP) certified automated analyzer (Adams HA-8160
HbA1C analyzer, Menarini, Italy). Total and high lipoprotein density (HDL) cholesterol, tri-
glycerides, and glucose levels were assayed by enzymatic methods (Roche, Basel, Switzerland).
Serum insulin concentrations were determined with a chemiluminescence-based assay
(Immulite1, Siemens, Italy). Serum uric acid was measured by the URICASE/POD method
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implemented in an autoanalyzer (Boehringer Mannheim, Mannheim, Germany). High sensi-
tivity C reactive protein (hsCRP) levels were assessed by an automated instrument (Cardio-
Phase1 hsCRP, Milan, Italy). White blood cell count was determined using an automated
particle counter (Siemens Healthcare Diagnostics ADVIA1 120/2120 Hematology System,
Italy). Erythrocytes sedimentation rate (ESR) was measured automatically by the stopped-flow
technique in a capillary microphotometer (Alifax Test 1 System Polverara, Italy). Fibrinogen
and complement C3 were measured by an automated nephelometric technology using the
BN™II System analyzer (Siemens Healthcare, Italy).
Statistical analysis
Variables with skewed distribution including triglycerides, fasting insulin, hsCRP, and ESR
were natural log transformed for statistical analyses. Continuous data are expressed as
means ± SD. Categorical variables were compared by χ2 test. Anthropometric and metabolic
differences between groups were assessed after adjusting for age, gender and BMI using a gen-
eralized linear model with post hoc Fisher’s least significant difference correction for pairwise
comparisons. A multivariable linear regression analysis was performed in order to evaluate the
independent contribution of HGI and other cardio-metabolic risk factors to IMT. A logistic
regression analysis adjusted for confounders was used to determine the association between
the study groups and vascular atherosclerosis (IMT >0.9 mm) [28]. A P value <0.05 was con-
sidered statistically significant. All analyses were performed using SPSS software programme
Version 17.0 for Windows.
Results
Calculation of HGI
Sample 1 consisting of 2,055 nondiabetic adult individuals (mean age 47.8±14.6 years) was
used to estimate the linear relationship between fasting plasma glucose and HbA1c. As shown
in Fig 1, fasting plasma glucose and HbA1c were highly correlated (r = 0.55) in a cohort with
widely varying glycemic control: mean HbA1c was 5.4 ±0.4%, and fasting plasma glucose 93±
11 mg/dl. The degree of correlation is very similar to the one observed in previous studies in
type 2 diabetic individuals [22]. Despite the good correlation, it is evident that there is a sub-
stantial scatter as well. Next, predicted HbA1c was calculated for 387 non-diabetic offspring
subjects included in sample 2 by inserting fasting plasma glucose concentration into the sam-
ple 1 linear regression equation (HbA1c = 0.0158  fasting glucose levels (mg/dl) +4.0311).
HGI was calculated by subtracting the predicted value of HbA1c from the observed HbA1c
levels, as previously described [22]. Study participants were stratified into tertiles (low, moder-
ate, or high HGI groups) according to their HGI value. The use of a tertile classification system
is consistent with previous HGI studies [22].
Cardio-metabolic characteristics
The mean age of the whole study sample was 37±10 years, 530 (47%) individuals were male,
and mean BMI was 29±6 kg/m2. Anthropometric and metabolic features of the study sample 2
stratified according to tertiles of HGI value are shown in Table 1. No significant differences
between the three study groups were observed with respect to gender. Subjects with high HGI
were older and heavier than individuals with low or moderate HGI. By design, individuals
with high HGI exhibited higher values of HbA1c, and lower concentrations of fasting plasma
glucose; however, no differences in 2h-post load glucose levels were observed amongst the
three study groups.
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After adjusting for age, gender and BMI, subjects with high HGI displayed higher levels of
triglycerides, uric acid, and fasting plasma insulin, and lower HDL cholesterol and insulin-
stimulated glucose disposal in comparison with individuals with low HGI. Additionally, after
adjusting for age, gender and BMI, subjects with high HGI displayed a significant increase of
all the inflammatory markers measured i.e. hsCRP, ESR, complement C3, fibrinogen and
white blood cell count in comparison with individuals with low HGI.
Atherosclerosis can be detected noninvasively in preclinical stages by measuring carotid
IMT, a well-established measure of early atherosclerosis that is largely utilized as a surrogate
marker for cardiovascular disease [29].
To estimate the independent contributor of HGI to IMT levels, we performed a linear
regression analysis in a model including gender, age, BMI, systolic and diastolic blood pres-
sure, total and HDL cholesterol, triglycerides, inflammatory markers, uric acid, fasting insulin
and insulin sensitivity, estimated by the insulin-stimulated glucose disposal. Comparison of
standardized coefficients allowing the determination of the relative strength of the association
of each variable with IMT (listed from strongest to weakest) is reported in Table 2. HGI was
the major contributor to IMT (β = 0.35; P = 0.001) followed by hsCRP (β = 0.34; P = 0.007),
ESR (β = 0.28; P = 0.02), and age (β = 0.17; P = 0.05). The full model explained 28% of IMT
variation.
After adjusting for age, gender, and BMI subjects with high HGI displayed a significant
increase in IMT as compared with individuals with low HGI (Table 1 and Fig 2A). A logistic
regression analysis adjusted age, gender, and BMI was used to determine the association
between the HGI values and subclinical vascular atherosclerosis, defined as IMT >0.9 mm
according to the ESH/ESC guidelines [28]. Subjects with high HGI showed a 2.7-fold increased
risk of having vascular atherosclerosis (OR 2.72, 95%CI 1.01–7.37) as compared with subjects
with low HGI (Table 1 and Fig 2B). When in the logistic regression model HGI values were
analyzed as continuous variable rather than a categorical variable (tertiles), we observed that
Fig 1. Linear relationship between HbA1c and fasting plasma glucose in the study sample 1.
https://doi.org/10.1371/journal.pone.0175547.g001
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each unit increase in HGI value was associated with a 5.2-fold increased risk of having vascular
atherosclerosis (OR 5.20, 95%CI 1.84–14.72).
Discussion
The risk of developing micro- and macro-vascular complications of both type 1 and type 2 dia-
betes is closely related to the chronic level of plasma glucose [30,31]. HbA1c is an integrated
measure of mean glycemia over the preceding 2–3 months, and is considered as the gold stan-
dard for measurement of glycemic control in subjects with diabetes. In addition, HbA1c is a
very good predictor of cardiovascular disease even in nondiabetic populations [2,3], and
recently, the ADA recommended the adoption of the HbA1c test for the diagnosis of diabetes
and prediabetes [1]. It is well established that HbA1c levels result from a posttranslational
modification of hemoglobin by glucose, and that the main factor influencing the rate of glyca-
tion in vivo is the prevailing concentration of plasma glucose. Nonetheless, discordances
between HbA1c levels and other measures of glycemic control have been reported [4–7].
Table 1. Anthropometric and metabolic characteristics of the study subjects stratified according to HGI tertiles.
Variables Low HGI
(1)
Moderate HGI
(2)
High HGI
(3)
P P
1 vs. 2
P
1 vs. 3
P
2 vs. 3
n (Male/Female) 129 (51/78) 129 (41/88) 129 (55/74) 0.18 0.24 0.70 0.09
Age (yr) 36±10 37±10 39±10 0.01* 0.32* 0.004* 0.07*
BMI (kg/m2) 29.0±7.6 29.5±7.4 32.9±8.6 0.001** 0.77** <0.0001** 0.001**
Waist circumference (cm) 94±17 947±16 103±18 <0.0001** 0.94** <0.0001** <0.0001**
SBP (mmHg) 121±13 121±18 124±17 0.31 0.37 0.12 0.50
DBP (mmHg) 77±9 78±11 79±11 0.12 0.81 0.10 0.06
HbA1c (%) [mmol/mol] 4.9±0.3
[30 mmol/mol]
5.3±0.2
[34 mmol/mol]
5.8±0.3
[40 mmol/mol]
<0.0001 <0.0001 <0.0001 <0.0001
Fasting glucose (mg/dl) 93±11 90±9 88±11 <0.0001 <0.0001 <0.0001 0.74
2-h glucose (mg/dl) 113±29 114±31 119±34 0.18 0.96 0.10 0.11
Fasting insulin (μU/ml) 10±5 11±7 15±9 0.005 0.89 0.005 0.003
Total cholesterol (mg/dl) 190±39 193±38 198±39 0.86 0.98 0.62 0.64
HDL (mg/dl) 53±13 52±13 48±11 0.07 0.70 0.03 0.08
Triglycerides (mg/dl) 102±52 103±58 134±82 0.03 0.96 0.02 0.02
Uric acid (mg/dl) 4.70±1.30 4.85±1.27 5.18±1.49 0.02 0.10 0.006 0.23
hsCRP (mg/l) 1.5±1.7 2.7±3.1 5.0±5.0 <0.0001 <0.0001 <0.0001 0.07
Fibrinogen (mg/dl) 274±68 286±62 309±70 0.002 0.27 0.001 0.01
Complement C3 (g/l) 1.07±0.18 1.15±0.22 1.25±0.23 0.07 0.22 0.02 0.22
ESR (mm/h) 12±11 14±11 16±13 0.02 0.16 0.008 0.15
White blood cell count (x109/l) 6358±1763 6800±2130 7698±2069 <0.0001 0.06 <0.0001 0.002
Insulin-stimulated glucose disposal (mg/min x Kg FFM) 10.6±3.7 10.5±4.4 8.4±4.7 0.03 0.89 0.02 0.02
Intima-media thickness (mm) 0.69±0.13 0.70±0.13 0.77±0.14 0.03 0.81 0.03 0.01
Vascular atherosclerosis
(OR 95%CI)
1
(Reference)
1.15
(0.37–3.57)
2.72
(1.01–7.37)
Data are means ± SD. Triglycerides, hsCRP, ESR, fasting, 1-h and 2-h insulin were log transformed for statistical analysis, but values in the table represent
a back transformation to the original scale. Categorical variables were compared by χ2 test. Comparisons between the three groups were performed using a
generalized linear model with post hoc Fisher’s least significant difference correction for pairwise comparisons. P values refer to results after analyses with
adjustment for age, gender, and BMI.
*P values refer to results after analyses with adjustment for gender.
**P values refer to results after analyses with adjustment for gender, and age. BMI = body mass index; SBP = systolic blood pressure; DBP = diastolic
blood pressure; HDL = high density lipoprotein; hsCRP = high sensitivity C-reactive protein; ESR = erythrocyte sedimentation rate.
https://doi.org/10.1371/journal.pone.0175547.t001
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Indeed, a number of individuals exhibit consistently higher or lower HA1c levels than those
that would be anticipated on the basis of fasting plasma glucose [22, 32], mean blood glucose
(self-monitored) [19,33] or continuous glucose monitoring [34, 35]. Differences in the glyca-
tion of hemoglobin between individuals with the same fasting plasma glucose values can be
assessed by the calculation of HGI [22,32]. HGI is a measure of the disagreement between the
observed value of HbA1c and the one predicted on the basis of blood glucose levels. Individu-
als with low and high HGI have HbA1c levels that are lower or higher than predicted, respec-
tively, compared with other individuals with similar blood glucose levels. It has been shown
that higher HGI is associated with increased risk of developing nephropathy and retinopathy
in patients with type 1 diabetes [21, 36], and with a greater risk of diabetic complications,
hypoglycemia and total mortality in a subgroup of the ACCORD population [22].
Overall, these data support the idea that a higher degree of non-enzymatic glycation of
intracellular proteins may play a pathogenic role in micro- and macro-vascular complications
related to hyperglycemia. If this is the case, it is conceivable that a higher HGI affecting intra-
cellular protein glycation process may increase the individual cardio-metabolic risk burden
among nondiabetic individuals. In the present study, we investigated the association between
HGI with insulin sensitivity, assessed by the gold standard euglycemic hyperinsulinemic
clamp, and carotid IMT, a validated measure of early stage of atherosclerosis [28,29], in a Cau-
casian cohort of nondiabetic offspring of type 2 diabetic patients. Impaired insulin sensitivity
is considered an important risk factor for atherosclerotic disease [37–39], and a key determi-
nant of cardiovascular risk factors, including visceral obesity, atherogenic dyslipidemia, and
hypertension, clustering within the metabolic syndrome [40]. We found that individuals with
high HGI exhibited a worse metabolic risk profile including higher whole body and visceral
adiposity, triglycerides, uric acid, fasting insulin, and lower HDL cholesterol and insulin-stim-
ulated glucose disposal in comparison with individuals with low HGI, independently of con-
founders such as age and gender. Notably, no significant differences in post-load glucose
concentrations were observed between the study groups, suggesting that the association
between HGI and cardo-metabolic risk factors were independent of other measures of glucose
Table 2. Multiple regression analysis evaluating IMT as dependent variable.
Dependent variable Independent contributors Coefficient β P
IMT HGI
hsCRP
ESR
Age
BMI
Gender
DBP
White blood cell count
Triglycerides
Fibrinogen
Total cholesterol
Fasting insulin
HDL
SBP
Complement C3
Insulin-stimulated glucose disposal
Uric acid
0.35
0.34
0.28
0.17
0.20
0.19
0.16
0.07
0.05
0.03
-0.06
-0.06
-0.04
-0.03
-0.03
0.006
0.002
0.001
0.007
0.02
0.05
0.11
0.11
0.26
0.43
0.74
0.76
0.59
0.61
0.71
0.84
0.74
0.96
0.98
Linear regression analysis in a model including gender, age, BMI, systolic and diastolic blood pressure, total and HDL cholesterol, triglycerides,
inflammatory markers, uric acid, fasting insulin, and insulin sensitivity, estimated by the insulin-stimulated glucose disposal.
IMT = intima-media thickness; BMI = body mass index; HGI = hemoglobin glycation index; hsCRP = high sensitivity C-reactive protein; ESR = erythrocyte
sedimentation rate; SBP = systolic blood pressure; DBP = diastolic blood pressure; HDL = high density lipoprotein.
https://doi.org/10.1371/journal.pone.0175547.t002
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homeostasis. Furthermore, we found a significant association between higher HGI and inflam-
matory status as subjects with high HGI displayed increased levels of inflammatory biomarkers
including hsCRP, complement C3, ESR, fibrinogen, and white blood cell count in comparison
to individuals with low HGI independently of age, gender, and BMI. As a result of the higher
cardio-metabolic risk burden, subjects with high HGI presented a significant increase in
carotid intima media thickness, a well validated indicator of subclinical atherosclerosis.
The mechanism by which elevated HGI are associated with increased risk of vascular ath-
erosclerosis is unsettled. One way for non-enzymatic glycosylation to cause both insulin resis-
tance and vascular atherosclerosis is by fostering advanced glycation end products (AGEs)
[41–43]. Notably, in subjects with diabetes increased HGI has been associated with higher lev-
els of AGEs [44]. AGEs interacting with their receptors (RAGE) on the cell membrane can
damage target cells by several mechanisms including altered function of intracellular proteins
modified by AGEs, activation of nuclear factor κ-B, causing a raise in gene expression of
Fig 2. IMT values (A), and OR 95%CI for vascular atherosclerosis, defined as IMT >0.9 (B), in the study
sample 2 stratified according to tertiles of HGI.
https://doi.org/10.1371/journal.pone.0175547.g002
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inflammatory mediators, and increased production of reactive oxygen species [41,42]. There is
evidence in animal models that oral advanced AGEs induce insulin resistance by altering insu-
lin receptor signaling leading to impaired glucose-uptake [45]. Moreover, in subjects with type
2 diabetes, it has been shown that baseline serum AGEs correlate with fasting insulin, and
indexes of insulin resistance, and an AGE-restricted diet for 4-months improves insulin sensi-
tivity [46]. Accordingly, we observed that individuals with high HGI had lower insulin sensi-
tivity and consequently higher levels of fasting insulin as compared with individuals with low
HGI independently of age, gender, and BMI.
In addition, chronic sub-clinical inflammation could be a unifying mechanistic factor link-
ing elevated HGI with vascular atherosclerosis. We found that individuals with higher HGI
displayed increased levels of a cluster of inflammatory markers including hsCRP, ESR, fibrino-
gen, white blood cell count, and complement C3 suggesting that a greater degree of non-enzy-
matic glycation may play a pathogenic role in inducing chronic sub-clinical inflammation.
Indeed, compelling evidence suggests that RAGE has a considerable role in innate immunity
[47], and inflammatory response is known to play a role in the development of atherosclerotic
cardiovascular disease [48,49]. It has been observed that subjects with diabetes treated with a
low AGEs diet for 6 weeks exhibit a significant reduction of serum AGEs levels and markers of
inflammation as hsCRP, and TNFα [50], thus reinforcing the role of AGEs in promoting sub-
clinical inflammation. Moreover, it has been reported that RAGEs are upregulated in the ath-
erosclerotic plaques of subjects with type 2 diabetes, and their overexpression is associated
with enhanced inflammatory reaction [50–53]. Because HGI has been shown to reflect the bur-
den of AGEs in the tissues, it is conceivable that activation of RAGE system may play a role in
the increased risk of vascular atherosclerosis observed in individuals with high HGI.
The present study has several strengths including the use of the gold standard hyperinsuli-
nemic euglycemic clamp for insulin sensitivity assessment, the demographically homogeneous
group of Italian subjects from European ancestry comprising both men and women, wealth of
detailed clinical, anthropometric and biochemical variables collected by trained professionals
according to a standardized protocol, the exclusion of confounding conditions potentially
affecting red cell turnover, such as anemia and major blood loss, the exclusion of subjects
treated with corticosteroids, lipid-lowering and anti-hypertensive drugs, the centralization of
laboratory analyses, the use of OGTT and HbA1c data to carefully exclude type 2 diabetes, the
use of a rigorously standardized HbA1c assay, and the ultrasound measure of carotid IMT per-
formed by an experienced examiner who was blinded to the clinical and biochemical data of
the participants.
Nevertheless, some limitations should be considered in the interpretation of the present
results. A first limitation of the study is that each diagnostic test including HbA1c and OGTT
was only performed once. Although such an approach reflects clinical practice, and is common
in epidemiological studies, the intra-individual variability of glucose parameters cannot be
taken into account, and some individuals might have been misclassified. In addition, the
observed differences in cardio-metabolic risk factors may be, in part, due to differences in age
and BMI between the HGI groups; however, all comparisons between groups were adjusted
for these potential confounders. Another limitation of the present study is its cross-sectional
design, making causal interpretations of associations between higher non-enzymatic glycation
of intracellular proteins assessed by HGI and risk of cardiovascular disease difficult. Indeed,
the current results reflect only an association with early atherosclerosis and not incident car-
diovascular disease. Moreover, it can also be argued that our results might have been affected
by the presence of a family history of type 2 diabetes. However, type 2 diabetes and cardiovas-
cular disease share common genetic determinants, and many individuals who develop cardio-
vascular disease have a family history of diabetes. Furthermore the study sample used to
Hemoglobin glycation index and sub-clinical atherosclerosis
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estimate the linear relationship between fasting plasma glucose and HbA1c displayed a mean
age higher than the one observed in the analysed cohort. It has been demonstrated that HbA1c
levels were positively associated with age in subjects without diabetes [54]. However in consid-
eration that a 0.014- and 0.010-unit increase in HbA1c per year has been descried in non-dia-
betic individuals participating to the Framingham Offspring Study and National Health and
Nutrition Examination Survey, respectively, we believe that the impact of the difference in the
age distribution between the two study samples (about 10 years) in HGI calculation was mar-
ginal. Finally, caution in generalizing these results is warranted since the current results are
only based on White individuals, and could not be extendible to other ethnic groups. Indeed,
previous studies have shown that HbA1c levels are higher among Blacks, Hispanics, American
Indians, and Asian Americans compared to Whites likely due to differences in hemoglobin
glycation or red cell survival [17,55].
In conclusion, the present findings support the notion that HGI may be a useful tool to
identify a subset of nondiabetic individuals conceivably harboring a higher risk of cardiovascu-
lar disease.
Author Contributions
Conceptualization: GS.
Data curation: MAM TVF ES EP FA AS.
Formal analysis: MAM TVF GS.
Funding acquisition: GS.
Investigation: MAM TVF ES EP FA AS.
Methodology: MAM TVF FP GS.
Project administration: GS.
Resources: FP GS.
Software: GS.
Supervision: FP GS.
Validation: MAM.
Visualization: MAM TVF.
Writing – original draft: GS.
Writing – review & editing: TVF.
References
1. American Diabetes Association. Standards of medical care in diabetes-2017. Diabetes Care 2017; 40
(Suppl 1): S11–S24 https://doi.org/10.2337/dc17-S005 PMID: 27979889
2. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. Glycated hemoglobin, dia-
betes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362:800–811 https://doi.org/
10.1056/NEJMoa0908359 PMID: 20200384
3. Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S. GHb is a better predictor of cardiovascular
disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Ber-
nardo Study. Diabetes Care 1996; 19:450–456 PMID: 8732708
4. Phillipou G, Phillips PJ. Intra-individual variation of glycohemoglobin: implications for interpretation and
analytical goals. Clin Chem 1993; 39:2305–8 PMID: 8222225
Hemoglobin glycation index and sub-clinical atherosclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0175547 April 20, 2017 10 / 13
5. Rohlfing C, Wiedmeyer HM, Little R, Grotz VL, Tennill A, England J, et al. Biological variation of glyco-
hemoglobin. Clin Chem 2002; 48:1116–8 PMID: 12089188
6. Gonen B, Rubenstein A, Rochman H, Tanega SP, Horwitz DL. Haemoglobin A1: an indicator of the met-
abolic control of diabetic patients. Lancet 1997; 2:734–737
7. Nathan DM, Singer DE, Hurxthal K, Goodson JD. The clinical information value of the glycosylated
hemoglobin assay. N Engl J Med 1984; 310:341–346 https://doi.org/10.1056/NEJM198402093100602
PMID: 6690962
8. Fukudome M, Nakazaki M, Fukushige E, Koriyama N, Ikeda Y, Kato K, et al. Inter-individual divergence
in the relationship between the values of plasma glucose and hemoglobin A1c in type 2 diabetes. Intern
Med 2009; 48:273–279 PMID: 19252347
9. Rodrıguez-Segade S, Rodrıguez J, Garcıa Lopez JM, Casanueva FF, Camina F. Estimation of the gly-
cation gap in diabetic patients with stable glycemic control. Diabetes Care 2012; 35:2447–2450 https://
doi.org/10.2337/dc11-2450 PMID: 22961579
10. Zafon C, Ciudin A, Valladares S, Mesa J, Simo R. Variables involved in the discordance between
HbA1c and fructosamine: the glycation gap revisited. PLoS One 2013; 8:e66696 https://doi.org/10.
1371/journal.pone.0066696 PMID: 23776693
11. Yudkin JS, Forrest RD, Jackson CA, Ryle AJ, Davie S, Gould BJ. Unexplained variability of glycated
haemoglobin in non-diabetic subjects not related to glycaemia. Diabetologia 1990; 33: 208–215 PMID:
2347434
12. Gould BJ, Davie SJ, Yudkin JS. Investigation of the mechanism underlying the variability of glycated
haemoglobin in non-diabetic subjects not related to glycaemia. Clin Chim Acta 1997; 260:49–64 PMID:
9101100
13. Kilpatrick ES, Maylor PW, Keevil BG. Biological variation of glycated hemoglobin. Implications for diabe-
tes screening and monitoring. Diabetes Care 1998; 21:261–264 PMID: 9539993
14. Rohlfing C, Wiedmeyer HM, Little R, Grotz VL, Tennill A, England J, et al. Biological variation of glyco-
hemoglobin. Clin Chem 2002; 48:1116–1118 PMID: 12089188
15. Cohen RM, Snieder H, Lindsell CJ, Beyan H, Hawa MI, Blinko S, et al. Evidence for independent herita-
bility of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins. Diabetes Care
2006; 29:1739–43 https://doi.org/10.2337/dc06-0286 PMID: 16873773
16. Leslie RD, Beyan H, Sawtell P, Boehm BO, Spector TD, Snieder H. Level of an advanced glycated end
product is genetically determined: a study of normal twins. Diabetes 2003; 52:2441–4 PMID: 12941787
17. Herman WH, Ma Y, Uwaifo G, Haffner S, Kahn SE, Horton ES, et al. Differences in A1C by race and
ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes
Care 2007; 30:2453–2457 https://doi.org/10.2337/dc06-2003 PMID: 17536077
18. Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood
glucose: implications for the diagnosis of diabetes. J Clin Endocrinol Metab 2012; 97:1067–72 https://
doi.org/10.1210/jc.2011-1894 PMID: 22238408
19. Soros AA, Chalew SA, McCarter RJ, Shepard R, Hempe JM. Hemoglobin glycation index: a robust
measure of hemoglobin A1c bias in pediatric type 1 diabetes patients. Pediatr Diabetes 2010; 11:455–
461 https://doi.org/10.1111/j.1399-5448.2009.00630.x PMID: 20088859
20. Wilson DM, Xing D, Cheng J, Beck RW, Hirsch I, Kollman C, et al. Persistence of individual variations in
glycated hemoglobin: analysis of data from the Juvenile Diabetes Research Foundation Continuous
Glucose Monitoring Randomized Trial. Diabetes Care 2011; 34:1315–1317 https://doi.org/10.2337/
dc10-1661 PMID: 21505208
21. McCarter RJ, Hempe JM, Gomez R, Chalew SA. Biological variation in HbA1c predicts risk of retinopa-
thy and nephropathy in type 1 diabetes. Diabetes Care 2004; 27:1259–1264 PMID: 15161772
22. Hempe JM, Liu S, Myers L, McCarter RJ, Buse JB, Fonseca V. The hemoglobin glycation index identi-
fies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care
2015; 38:1067–74 https://doi.org/10.2337/dc14-1844 PMID: 25887355
23. Sesti G, Hribal ML, Procopio T, Fiorentino TV, Sciacqua A, Andreozzi F, et al. Low circulating insulin-
like growth factor-1 levels are associated with high serum uric acid in nondiabetic adult subjects. Nutr
Metab Cardiovasc Dis 2014; 24: 1365–1372 https://doi.org/10.1016/j.numecd.2014.06.012 PMID:
25149895
24. Staiger H, Stanča´kova´ A, Zilinskaite J, Va¨nttinen M, Hansen T, Marini MA, et al. A candidate type 2 dia-
betes polymorphism near the HHEX locus affects acute glucose-stimulated insulin release in European
populations: results from the EUGENE2 study. Diabetes 2008; 57:514–517 https://doi.org/10.2337/
db07-1254 PMID: 18039816
Hemoglobin glycation index and sub-clinical atherosclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0175547 April 20, 2017 11 / 13
25. Marini MA, Frontoni S, Succurro E, Arturi F, Sciacqua A, Hribal ML, et al. Insulin sensitivity, and β-cell
function in relation to hemoglobin A1C. Nutr Metab Cardiovasc Dis 2014; 24: 27–33 https://doi.org/10.
1016/j.numecd.2013.01.011 PMID: 23601331
26. Laakso M, Zilinskaite J, Hansen T, Boesgaard TW, Va¨nttinen M, Stanca´kova´ A, et al. Insulin sensitivity,
insulin release and GLP-1 levels in subjects with IFG and/or IGT in the EUGENE2 study. Diabetologia
2008; 51:502–511 https://doi.org/10.1007/s00125-007-0899-2 PMID: 18080106
27. Marini MA, Succurro E, Castaldo E, Cufone S, Arturi F, Sciacqua A, et al. Cardio-metabolic risk profiles
and carotid atherosclerosis in individuals with prediabetes identified by fasting glucose, postchallenge
glucose, and hemoglobin A1c criteria. Diabetes Care 2012; 35:1144–1149 https://doi.org/10.2337/
dc11-2032 PMID: 22399698
28. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines
on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European
Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice
(constituted by representatives of 10 societies and by invited experts) Developed with the special contri-
bution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart
J 2016; 37:2315–81 https://doi.org/10.1093/eurheartj/ehw106 PMID: 27222591
29. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid artery intima and
media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med 1999;
340:14–22 https://doi.org/10.1056/NEJM199901073400103 PMID: 9878640
30. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and pro-
gression of long-term complications in IDDM. N Engl J Med 1993; 329: 977–983 https://doi.org/10.
1056/NEJM199309303291401 PMID: 8366922
31. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with
macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observa-
tional study. BMJ 2000; 321:405–412 PMID: 10938048
32. Kim JI, Stevens RJ, Holman RR. The haemoglobin glycation index is an independent risk factor for
microvascular complications in UKPDS patients with newly diagnosed type 2 diabetes (Abstract). Dia-
betes 2005; 54:A244–A245
33. Hempe JM, Soros AA, Chalew SA. Estimated average glucose and self-monitored mean blood glucose
are discordant estimates of glycemic control. Diabetes Care 2010; 33:1449–1451 https://doi.org/10.
2337/dc09-1498 PMID: 20357368
34. Wilson DM, Xing D, Cheng J, Beck RW, Hirsch I, Kollman C, et al. Persistence of individual variations in
glycated hemoglobin: analysis of data from the Juvenile Diabetes Research Foundation Continuous
Glucose Monitoring Randomized Trial. Diabetes Care 2011; 34:1315–1317 https://doi.org/10.2337/
dc10-1661 PMID: 21505208
35. Diabetes Research in Children Network (DirecNet) Study Group; Wilson DM, Kollman C. Relationship
of A1C to glucose concentrations in children with type 1 diabetes: assessments by high-frequency glu-
cose determinations by sensors. Diabetes Care 2008; 31:381–385 https://doi.org/10.2337/dc07-1835
PMID: 18056888
36. Hempe JM, Gomez R, McCarter RJ Jr, Chalew SA. High and low hemoglobin glycation phenotypes in
type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications 2002;
16:313–320 PMID: 12200073
37. Howard G, O’Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, et al. Insulin sensitivity and ath-
erosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation 1996; 93:
1809–1817 PMID: 8635260
38. Rutter MK, Meigs JB, Sullivan LM, D’Agostino RB Sr., Wilson PW. Insulin resistance, the metabolic syn-
drome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005; 54:
3252–3257. PMID: 16249452
39. Cardellini M, Marini MA, Frontoni S, Hribal ML, Andreozzi F, Perticone F, et al. Carotid artery intima-
media thickness is associated with insulin-mediated glucose disposal in nondiabetic normotensive off-
spring of type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007; 292: E347–352 https://doi.org/
10.1152/ajpendo.00291.2006 PMID: 16968812
40. Reaven G. Role of insulin resistance in human disease. Diabetes 1988; 37:1595–607 PMID: 3056758
41. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813–
20 https://doi.org/10.1038/414813a PMID: 11742414
42. Vlassara H, Uribarri J. Advanced glycation end products (AGE) and diabetes: cause, effect, or both?.
Curr Diab Rep 2014; 14:453 https://doi.org/10.1007/s11892-013-0453-1 PMID: 24292971
43. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the
development of diabetic vascular injury. Circulation 2006; 114:597–605 https://doi.org/10.1161/
CIRCULATIONAHA.106.621854 PMID: 16894049
Hemoglobin glycation index and sub-clinical atherosclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0175547 April 20, 2017 12 / 13
44. Felipe DL, Hempe JM, Liu S, Matter N, Maynard J, Linares C, et al. Skin intrinsic fluorescence is associ-
ated with hemoglobin A(1c) and hemoglobin glycation index but not mean blood glucose in children with
type 1 diabetes. Diabetes Care 2011; 34:1816–20 https://doi.org/10.2337/dc11-0049 PMID: 21636794
45. Cai W, Ramdas M, Zhu L, Chen X, Striker GE, Vlassara H. Oral advanced glycation end products
(AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1
and sirtuin 1. Proc Natl Acad Sci U S A 2012; 109:15888–93 https://doi.org/10.1073/pnas.1205847109
PMID: 22908267
46. Uribarri J, Cai W, Ramdas M, Goodman S, Pyzik R, Chen X, et al. Restriction of advanced glycation
end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and
SIRT1. Diabetes Care 2011; 34:1610–6 https://doi.org/10.2337/dc11-0091 PMID: 21709297
47. Rojas A, Pe´rez-Castro R, Gonza´lez I, Delgado F, Romero J, Rojas I. The emerging role of the receptor
for advanced glycation end products on innate immunity. Int Rev Immunol 2014; 33:67–80 https://doi.
org/10.3109/08830185.2013.849702 PMID: 24266871
48. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in
the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836–843 https://doi.org/
10.1056/NEJM200003233421202 PMID: 10733371
49. Verma S, Wang CH, Li SH Dumont AS, Fedak PW, Badiwala MV, Dhillon B, et al. A self−fulfilling proph-
ecy: C−reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;
106:913–919 PMID: 12186793
50. Vlassara H, Cai W, Crandall J, Goldberg T, Oberstein R, Dardaine V, et al. Inflammatory mediators are
induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A
2002; 99:15596–601 https://doi.org/10.1073/pnas.242407999 PMID: 12429856
51. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, et al. The receptor RAGE as a progres-
sion factor amplifying arachidonate-dependent inflammatory and proteolytic response in human athero-
sclerotic plaques: role of glycemic control. Circulation 2003; 108:1070–1077 https://doi.org/10.1161/
01.CIR.0000086014.80477.0D PMID: 12912808
52. Kilhovd BK, Juutilainen A, Lehto S, Ro¨nnemaa T, Torjesen PA, Hanssen KF, et al. Increased serum lev-
els of advanced glycation end-products predict total, cardiovascular and coronary mortality in women
with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 2007; 50:1409–17
https://doi.org/10.1007/s00125-007-0687-z PMID: 17479244
53. Kilhovd BK, Juutilainen A, Lehto S, Ro¨nnemaa T, Torjesen PA, Birkeland KI, et al. High serum levels of
advanced glycation end products predict increased coronary heart disease mortality in nondiabetic
women but not in nondiabetic men: a population-based 18-year follow-up study. Arterioscler Thromb
Vasc Biol 2005; 25:815–20 https://doi.org/10.1161/01.ATV.0000158380.44231.fe PMID: 15692098
54. Pani LN, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, et al. Effect of aging on A1C levels in indi-
viduals without diabetes: evidence from the Framingham Offspring Study and the National Health and
Nutrition Examination Survey 2001–2004. Diabetes Care. 2008; 31:1991–6 https://doi.org/10.2337/
dc08-0577 PMID: 18628569
55. Herman WH, Cohen RM. Racial and ethnic differences in the relationship between HbA1c and blood
glucose: implications for the diagnosis of diabetes. J Clin Endocrinol 2012; Metab 97:1067–72.
Hemoglobin glycation index and sub-clinical atherosclerosis
PLOS ONE | https://doi.org/10.1371/journal.pone.0175547 April 20, 2017 13 / 13
